Pfizer recalls epilepsy medicine

NewsGuard 100/100 Score

Pfizer has voluntarily recalled one lot (40,000 bottles) of 100 mg capsules of its epilepsy medication, Neurontin, after a manufacturing mechanical failure resulted in some bottles containing empty or partially filled capsules.

Pfizer said only 100 mg strength capsules from lot #15224V—distributed in October and November, 2004—are included in the recall. The production lot was distributed only in the United States. No other Neurontin lots were affected.

The company said it is possible that patients taking Neurontin to control epilepsy could experience seizures from a missed dose of the product.

Although pharmacists and Pfizer distributors were notified on February 23 of the recall and pharmacists were instructed to immediately contact any of their customers using Neurontin, Pfizer wants to ensure full patient awareness. The company has worked closely with the FDA throughout the recall process.

Patients should not stop taking Neurontin before consulting with their physician. If they filled a prescription for the product in 100 mg strength between October 1, 2004 and March 15, 2005 and are concerned that any unused capsules may be part of the recalled lot, they should contact their pharmacist.

If consumers have questions about the recall, they should contact Pfizer Medical Information at 1-800-438-1985.

Pfizer said the recall of the affected lot will not result in a shortage of Neurontin 100 mg capsules.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Renaissance of "food as medicine" in modern clinical trials